A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03124368 |
|
Recruitment Status :
Recruiting
First Posted : April 21, 2017
Last Update Posted : July 18, 2018
|
Sponsor:
Achillion Pharmaceuticals
Information provided by (Responsible Party):
Achillion Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of this study is to determine whether ACH-0144471 can increase blood C3 levels in participants with low C3 levels due to either C3G or IC-MPGN.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| C3 Glomerulonephritis Dense Deposit Disease Membranoproliferative Glomerulonephritis, Type II C3 Glomerulopathy Immune Complex Mediated Membranoproliferative Glomerulonephritis | Drug: ACH-0144471 | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 10 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) |
| Actual Study Start Date : | August 9, 2017 |
| Estimated Primary Completion Date : | September 2018 |
| Estimated Study Completion Date : | December 2018 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
C3 glomerulopathy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Sentinel Group 1
All participants will receive ACH-0144471 during the treatment period.
|
Drug: ACH-0144471
Participants will receive study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period)
Other Names:
|
|
Experimental: Group 2
All participants will receive ACH-0144471 during the treatment period.
|
Drug: ACH-0144471
Participants will receive study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period)
Other Names:
|
Primary Outcome Measures :
- Change From Baseline in Blood C3 levels at Day 14 [ Time Frame: Baseline, Day 14 ]
Secondary Outcome Measures :
- Serious Adverse Events (SAEs), Grade 3 or Higher Adverse Events (AEs), and AEs Leading to Discontinuation [ Time Frame: up to Day 49 ]
- Time (in Days) to Achieving Peak C3 Levels From the First Day of Dosing [ Time Frame: Day 14 ]
- Pharmacokinetics: Area Under the Curve (AUC) [ Time Frame: Days 1 & 7 ]
- Pharmacokinetics: Maximum Plasma Concentration (Cmax) [ Time Frame: Days 1 & 7 ]
- Profile of Pharmacokinetics: Time to maximum concentration (Tmax) [ Time Frame: Days 1 & 7 ]
- Change from Baseline in Biomarkers of Alternative Pathway (AP) activity (AP Wieslab, factor D, and Bb) [ Time Frame: Baseline, Day 14 ]
- Relationship between ACH-0144471 exposure and changes in C3 levels and other biomarkers of alternative pathway activity (AP Wieslab, factor D, and Bb) [ Time Frame: Day 14 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years to 65 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Must have a clinical diagnosis of C3G (C3 glomerulonephritis [C3GN] or dense deposit disease [DDD], the 2 types of C3G) or idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN) by renal biopsy for at least 3 months prior to dosing, with the pathologic diagnosis verified by review of the renal biopsy by the study central pathologist
- C3 must be <50% of the lower limit of normal
- C4 must be >90% of the lower limit of normal
- Must be willing to comply with study-specific vaccination requirements for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis strains A, C, W, and Y
- Negative pregnancy test for females prior to dosing and throughout the study
Exclusion Criteria:
- History of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant. Individuals receiving renal replacement therapy are also excluded
- Evidence of monoclonal gammopathy of unclear significance (MGUS), infections, malignancy, autoimmune diseases, or other conditions to which C3 glomerulopathy or IC-MPGN may be secondary
- Estimated glomerular filtration rate (eGFR; using MDRD equation) <45 mL/min/1.73 m2 at the time of screening or at any time over the preceding four-weeks
- Receipt of eculizumab at any dose or interval within the past 75 days prior to dosing
- Use of tacrolimus or cyclosporine within 2 weeks of the first dose of ACH-0144471
- History of febrile illness, a body temperature >38°C, or other evidence of a clinically significant active infection, within 14 days prior to study drug administration
- History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection
- Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or patients with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration
NOTE: Additional inclusion/exclusion criteria may apply, per protocol.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03124368
Contacts
| Contact: Clinical Operations | 203-752-5566 | C3GTrialInquiries@achillion.com |
Locations
| Australia | |
| The Royal Melbourne Hospital | Recruiting |
| Melbourne, Australia | |
| Belgium | |
| ZNA Middelheim | Recruiting |
| Antwerpen, Belgium | |
| Netherlands | |
| Leiden University | Not yet recruiting |
| Leiden, Netherlands | |
| Amalia Children's Hospital | Recruiting |
| Nijmegen, Netherlands | |
| Radboud University Nijmegen Medical Centre | Recruiting |
| Nijmegen, Netherlands | |
Sponsors and Collaborators
Achillion Pharmaceuticals
| Responsible Party: | Achillion Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03124368 History of Changes |
| Other Study ID Numbers: |
ACH471-201 2016-003525-42 ( EudraCT Number ) |
| First Posted: | April 21, 2017 Key Record Dates |
| Last Update Posted: | July 18, 2018 |
| Last Verified: | July 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
| Product Manufactured in and Exported from the U.S.: | Yes | |
Keywords provided by Achillion Pharmaceuticals:
|
factor D fD alternative pathway complement mediated disease idiopathic MPGN MPGN Type I |
MPGN Type II MPGN Type III Primary MPGN MCGN Mesangiocapillary Glomerulonephritis |
Additional relevant MeSH terms:
|
Glomerulonephritis Glomerulonephritis, Membranoproliferative Nephritis |
Kidney Diseases Urologic Diseases Immune System Diseases |